The safety profile and angioarchitectural changes after acute targeted embolization of ruptured arteriovenous malformations.

angioarchitecture arteriovenous malformation embolization intracranial hemorrhage treatment vascular disorders

Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
07 May 2021
Historique:
received: 30 04 2020
accepted: 22 09 2020
medline: 8 5 2021
pubmed: 8 5 2021
entrez: 7 5 2021
Statut: epublish

Résumé

The aim of this study was to 1) compare the safety and efficacy of acute targeted embolization of angiographic weak points in ruptured brain arteriovenous malformations (bAVMs) versus delayed treatment, and 2) explore the angioarchitectural changes that follow this intervention. The authors conducted a retrospective analysis of a prospectively acquired database of ruptured bAVMs. Three hundred sixteen patients with ruptured bAVMs who presented to the hospital within 48 hours of ictus were included in the analysis. The first analysis compared clinical and functional outcomes of acutely embolized patients to those with delayed management paradigms. The second analysis compared these outcomes of patients with acute embolization to those with angiographic targets who did not undergo acute embolization. Finally, a subset of 20 patients with immediate postembolization angiograms and follow-up angiograms within 6 weeks of treatment were studied to determine the angioarchitectural changes after acute targeted embolization. Kaplan-Meier curves for survival between the groups were devised. Multivariate logistical regression analysis was conducted. There were three deaths (0.9%) and an overall rerupture rate of 4.8% per year. There was no statistical difference in demographic variables, mortality, and rerupture rate between patients with acute embolization and those with delayed management. Patients with acute embolization were more likely to present functionally worse (46.9% vs 69.8%, modified Rankin Scale score 0-2, p = 0.018) and to require an adjuvant therapy (71.9% vs 26.4%, p < 0.001). When comparing acutely embolized patients to those nonacutely embolized angiographic targets, there was a significant protective effect of acute targeted therapy on rerupture rate (annual risk 1.2% vs 4.3%, p = 0.025) and no difference in treatment complications. Differences in the survival curves for rerupture were statistically significant. Multivariate analyses significantly predicted lower rerupture in acute targeted treatment and higher rerupture in those with associated aneurysms, deep venous anatomy, and higher Spetzler-Martin grade. All patients with acute embolization experienced complete obliteration of the angiographic weak point with various degrees of resolution of the nidus; however, some had spontaneous recurrence of their bAVM, while others had spontaneous resolution over time. No patients developed new angiographic weak points. This study demonstrates that acute targeted embolization of angiographic weak points, particularly aneurysms, is technically safe and protective in the early phase of recovery from ruptured bAVMs. Serial follow-up imaging is necessary to monitor the evolution of the nidus after targeted and definitive treatments. Larger prospective studies are needed to validate these findings.

Identifiants

pubmed: 33962377
doi: 10.3171/2020.9.JNS201558
pii: 2020.9.JNS201558
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1598-1607

Auteurs

Ann Mansur (A)

1Division of Neurosurgery, Department of Surgery, Faculty of Medicine, University of Toronto.

Alex Kostynskyy (A)

2Division of Neuroradiology, Department of Medical Imaging, and.

Timo Krings (T)

2Division of Neuroradiology, Department of Medical Imaging, and.

Ronit Agid (R)

2Division of Neuroradiology, Department of Medical Imaging, and.

Ivan Radovanovic (I)

3Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, University Health Network, University of Toronto; and.
4Krembil Neuroscience Center, University Health Network, Toronto, Ontario, Canada.

Vitor Mendes Pereira (V)

2Division of Neuroradiology, Department of Medical Imaging, and.
3Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, University Health Network, University of Toronto; and.

Classifications MeSH